MicroRNA Binding Site Polymorphisms are Associated with the Development of Gastric Cancer

Document Type : Research Articles

Authors

• Jamal Asgarpour ¹
• Jamshid Mehrzad ¹
• Seyyed Abbas Tabatabaei Yazdi ²

¹ Islamic Azad University, Neyshabur, Iran

² Mashhad University of Medical Sciences

https://doi.org/10.22067/jcmr.v9i2.71487

Abstract

MicroRNAs (miRNAs) binding to the 3'-untranslated regions (3'-UTRs) of messenger RNAs (mRNAs), affect several cellular mechanisms such as translation, differentiation, tumorigenesis, carcinogenesis and apoptosis. The occurrence of genetic polymorphisms in 3'-UTRs of target genes affect the binding affinity of miRNAs with the target genes resulting in their altered expression. The current case control study of 100 samples (50% cancer patients and 50% health persons as control) was aimed to evaluate the genotyping of microRNA single nucleotide polymorphisms (SNPs) located at the binding site of the 3' UTR of C14orf101 (rs4901706) and mir-124 (- rs531564) genes and their correlations with gastric cancer (GC) development. The Statistical analysis results indicated the significant association of AG development risk with the SNPs located in the 3'-UTR of C14orf101 and mir-124. It could be concluded from the results that these genes are associated with the gastric adenocarcinoma.

Keywords

• Carcinogenesis
• C14orf101 polymorphism
• Mir-124
• Gastric cancer development

20.1001.1.20089147.2017.9.2.4.1

References

1.Abediankenari S., Shokrzadeh M., Aminjan H. H., Nasri N. and Alizadeh A. (2013) Evaluation of caspase3 and 9 gene polymorphisms in gastric cancer patients in Mazandaran province: a brief report. Tehran University Medical Journal 71.

2.Babaei M., Pourfarzi F., Yazdanbod A., Chiniforush M. M., Derakhshan M. H., Mousavi S. M., Samadi F. and Rahimi G. (2010) Gastric cancer in Ardabil, Iran--a review and update on cancer registry data. Asian Pacific Journal of Cancer Prevention (APJCP) 11:595-599.

3.Barni S., Lissoni P., Crispino S., Cattaneo G., Rovelli F., Fumagalli G. and Tancini G. (1988) Neuroimmunomodulation in cancer patients: correlations between melatonin and beta-endorphin blood levels and T helper/suppressor ratio. The International Journal of Biological Markers 3:82-86.

4.Compare D., Rocco A. and Nardone G. (2010) Risk factors in gastric cancer. European Review for Medical and Pharmacological Sciences 14:302-308.

5.Jemal A., Siegel R., Xu J. and Ward E. (2010) Cancer statistics, 2010. CA: A Cancer Journal for Cinicians 60:277-300.

6. Lerner A. B., Case J. D., Takahashi Y., Lee T. H. and Mori W. (1958) Isolation of melatonin, the pineal gland factor that lightens melanocyteS1. Journal of the American Chemical Society 80:2587-2587.

7.Li Y.-L., Tian Z., Zhang J.-B. and Fu B.-Y. (2012) CDH1 promoter polymorphism and stomach cancer susceptibility. Molecular Biology Reports 39:1283-1286.

8.Lin X., Zhao Y., Song W.-m. and Zhang B. (2015) Molecular classification and prediction in gastric cancer. Computational and Structural Biotechnology Journal 13:448-458.

9.Siewert J. and Maruyama K. (1995) “What's new in gastric cancer?”—Introduction. World Journal of Surgery 19:483-483.

10.Tepes B. (2009) Can gastric cancer be prevented. Journal of Physiology and Pharmacology 60:71-77.